FDA Brief

Warning letters Drugs

FDA warning letter to

Brassica Pharma Pvt. Ltd.

High riskIssued Jul 11, 2024Posted Jul 23, 2024Center for Drug Evaluation and Research (CDER)

FDA warns Brassica Pharma over fabricated sterility and environmental data and poor aseptic controls for sterile drugs.

What happened

FDA inspected Brassica Pharma's drug manufacturing facility from January 15 to 19, 2024. It found that the firm did not test every batch for sterility and fabricated sterility and environmental monitoring records. Four sterility tests during the inspection failed, including one U.S. product, and investigators saw 37 ISO 5 and 17 ISO 7 action-level environmental excursions plus poor aseptic practices, gowning, media fills, airflow, sterilization validation, facility pressure, and cleaning.

What FDA found

  1. The firm did not test every batch for sterility and fabricated sterility and environmental monitoring records.

    21 CFR 211.194(a)
  2. The firm did not follow adequate procedures to prevent microbial contamination and did not adequately validate aseptic and sterilization processes.

    21 CFR 211.113(b)
  3. Aseptic processing areas and lines were not adequately designed or controlled to prevent contamination; pressure reversals and an insufficient environmental monitoring program were found.

    21 CFR 211.42(c)(10)
  4. The firm did not adequately clean equipment that contacts sterile tubes and did not validate cleaning under routine conditions.

    21 CFR 211.67(a) and 211.67(b)

What FDA wants

FDA asks Brassica to provide a comprehensive data-integrity investigation, patient-risk assessments, and global corrective action plans, plus independent assessments of its laboratory, aseptic processing and environmental monitoring. The letter does not state a response deadline.

Who should pay attention

  • companies buying sterile ophthalmic or other finished drugs from this contract manufacturer
  • brands relying on Brassica for U.S. sterile drug supply
  • quality teams auditing sterile contract manufacturers and data integrity

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk